drugset / Trial / NCT04062565

Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH

NCT04062565

Phase 3 Recruiting 20 enrolled University of Arizona
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if there is a greater effect to patients with advanced pulmonary arterial hypertension (PAH) by using a combination of two drugs, Treprostinil and Riociquat versus Treprostinil alone

Timeline

Start
2019-03-25
Primary completion
2025-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Riociguat Other / unclassified 0.5 mg
Subject Treprostinil Other / unclassified Other